Autologous mesenchymal stem cell therapy - Pharmicell

Drug Profile

Autologous mesenchymal stem cell therapy - Pharmicell

Alternative Names: Cellgram-ED; Cerecellgram-spine; Hearticellgram-AMI; Immunocellgram; Impocellgram; Livercellgram; Lungcellgram; MSC 1 - FCB Pharmicell; MSC 2 - FCB Pharmicell

Latest Information Update: 28 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FCB-Pharmicell
  • Developer Asan Medical Center; Nonindustrial source; Pharmicell; Samsung Medical Center; Yonsei University Health System
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase III Stroke
  • Phase II/III Spinal cord injuries
  • Phase II Adult respiratory distress syndrome; Liver cirrhosis
  • Phase I/II Graft-versus-host disease; Parkinson's disease; Renal transplant rejection
  • Phase I Erectile dysfunction
  • Clinical Phase Unknown Brain injuries; Cerebral haemorrhage; Solid tumours
  • Preclinical Pulmonary fibrosis

Most Recent Events

  • 01 Mar 2016 Pharmicell completes a phase II trial in Cirrhosis in South Korea (Intra-arterial) (NCT01875081)
  • 01 Jul 2015 Phase-I clinical trials in Erectile dysfunction in South Korea (Intracavernous) (NCT02344849)
  • 25 Jun 2015 Pharmicell plans a phase I trial for Peripheral arterial disorders (in patients with critical limb ischaemia) in South Korea (NCT02477540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top